ライフサイエンスコーパス: live @3 vaccine

1 ttenuated EEEV variants have been applied as live EEEV vaccines.

2 vaccines and most other strategies involving live virus vaccines.

3 ing immunization of a 78-year-old woman with live zoster vaccine.

4 design of a safe alternative to the existing live smallpox vaccine.

5 th -19% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

6 culated for the inactivated vaccines and the live attenuated vaccine.

7 ping a safe and potentially more efficacious live attenuated vaccine.

8 l tropism of a virus is a new approach for a live attenuated vaccine.

9 o understand virus biology and develop novel live attenuated vaccines.

10 n vivo and supports targeting the SH gene in live attenuated vaccines.

11 ations are good candidates for the design of live attenuated vaccines.

12 r antiviral discovery and development of new live attenuated vaccines.

13 use of non-toxigenic C. difficile strains as live attenuated vaccines.

14 ty and activity is a strategy for generating live-attenuated vaccines.

15 ize may be more informative on the safety of live-attenuated vaccines.

16 option as safe, immunogenic, and protective live-attenuated vaccines.

17 ortant determinants of the immunogenicity of live-virus oral vaccines.

18 l adjuvants and licensed vaccines, including live attenuated BCG vaccine.

19 should improve the safety and efficacy of a live attenuated RSV vaccine.

20 athology is a key correlate of the safety of live mycobacterial vaccines.

21 value of including such a mutation in future live attenuated RSV vaccines.

22 eviously exposed to DENV4 infections or to a live attenuated DENV4 vaccine.

23 d may translate into improved manufacture of live-attenuated hRSV vaccines.

24 ects against virulent challenges, similar to live L. monocytogenes vaccines.

25 on polio vaccines and, eventually, for other live-attenuated viral vaccines.

26 lenge model to better evaluate the candidate live attenuated dengue vaccines.

27 une responses elicited by vaccination with a live attenuated type II vaccine.

28 have emerged about the effectiveness of the live attenuated influenza vaccine.

29 H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine.

30 oing testing, including genetically modified live-attenuated parasite vaccines.

31 ide novel targets for the rational design of live attenuated flavivirus vaccine.

32 safe and effective platform for creation of live attenuated RNA viral vaccines.

33 he rational development of other efficacious live attenuated flavivirus vaccines.

34 nstrating that this mutant is an attenuated, live, transmission-blocking vaccine.

35 development of safe, stable, and protective live-attenuated arenavirus vaccines.

36 vaccine as well as further reduce costs for live-attenuated oral polio vaccines.

37 enic influenza virus and immunization with a live attenuated influenza virus vaccine.

38 hallenge the level of protection provided by live attenuated oral rotavirus vaccines.

39 ter randomized controlled trial [cRCT]) used live attenuated influenza vaccine, 11 (7 cRCTs) used ina

40 Here we report maternal vaccination using a live-attenuated ZIKV vaccine (3'UTR-Delta10-LAV) in a pr

41 We propose that this live attenuated vaccine acts like a silent natural infec

42 natural infection and strategies to develop live attenuated vaccines against flaviviral species.IMPO

43 s study may aid in the design of efficacious live attenuated vaccines against PEDV, as well as other

44 To explore the potential of a live rAd vaccine against malaria, we prepared a viable a

45 A similar approach may guide the design of live-attenuated vaccines against Lassa and other arenavi

46 ly good target for developing antivirals and live-attenuated viral vaccines against deadly arenavirus

47 However, live attenuated vaccines also induce strong CD8 T cell r

48 VE did not appear to be different for live-attenuated and inactivated vaccines among children

49 4 T cell responses elicited by a tetravalent live attenuated dengue vaccine and show that they resemb

50 ile platform for the clinical development of live attenuated HCMV-vectored vaccines and immunotherapi

51 confirmed in 210 (18%) of 1173 recipients of live attenuated influenza vaccine and 105 (18%) of place

52 dren were randomly assigned, 1174 to receive live attenuated influenza vaccine and 587 to receive pla

53 or the observed reduced effectiveness of the live attenuated influenza vaccine and highlight the unde

54 may be a novel target for rational design of live attenuated vaccines and antiviral drugs.

55 sible association between revaccination with live attenuated vaccines and off-target infections are n

56 hlight the distinct evolutionary dynamics of live attenuated virus vaccines and have important implic

57 r quality control of new lots of the current live-attenuated vaccine and provide insight for the rati

58 nform the development of rationally-designed live-attenuated vaccines and antivirals for control of o

59 applied to current commercial PRRSV modified live-virus (MLV) vaccines and other candidate vaccines.

60 women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the express

61 to wild-type CHIKV, two CHIKV vaccines, or a live-attenuated MAYV vaccine, and challenged with MAYV.

62 rts superseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seas

63 Live attenuated vaccines appear to be the most effective

64 The live attenuated influenza vaccine appears to protect par

65 Experimental live attenuated RSV vaccines are grown in Vero cells, bu

66 Novel live attenuated vaccines are being developed that promis

67 Live attenuated vaccines are commonly used in the poultr

68 Live attenuated vaccines are considered the most viable

69 Live attenuated vaccines are more immunogenic and have t

70 Live attenuated vaccines are traditionally generated by

71 isease in high-mortality settings means that live oral rotavirus vaccines are still likely to provide

72 ger studies of intradermal administration of live, attenuated zoster vaccine are needed to provide co

73 sidering rotavirus vaccine introduction that live, oral rotavirus vaccines are effective in high-chil

74 Two doses of live-attenuated varicella-zoster vaccine are recommended

75 ults suggest that EHV-1 KyA may be used as a live attenuated EHV-1 vaccine as well as a prophylactic

76 ion may serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for

77 tivity can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for

78 ong children whose last vaccine received was live compared with inactivated vaccine, as well as concu

79 l vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing prot

80 Our aim is to estimate the efficacy of live oral rotavirus vaccines at each point during follow

81 Eligible patients received live zoster vaccine at investigators' discretion.

82 al, we assessed the efficacy and safety of a live attenuated influenza vaccine based on Russian-deriv

83 consideration should be taken when designing live attenuated vaccines based on deletions of nonstruct

84 se findings provide a pathway for developing live attenuated virus vaccines based on engineering the

85 Moreover, live oral MAV-1 vaccine better protected against a respi

86 We have developed the live attenuated nasal pertussis vaccine BPZE1, currently

87 y exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, develop

88 We show that live influenza vaccines can contain underappreciated sub

89 excellent safety profile and high stability, live-attenuated CDV vaccines can retain residual virulen

90 Therefore, we generated a live attenuated avian H3N8 vaccine candidate and demonst

91 BACKGROUNDThe live attenuated BPZE1 vaccine candidate induces protecti

92 We generated a live attenuated H3N8 vaccine candidate and demonstrated

93 test the protective potential of the novel, live attenuated pertussis vaccine candidate BPZE1.

94 ures of the infection in humans and tested a live-attenuated MAYV vaccine candidate (MAYV/IRES).

95 mice and highlights the potential role of a live-attenuated MAYV vaccine candidate in host's protect

96 nd efficacy and represents a promising novel live-attenuated RSV vaccine candidate.

97 ra from a phase 2 clinical trial of Takeda's live-attenuated tetravalent dengue vaccine candidate (TA

98 To control TMUV infection, a live-attenuated vaccine candidate of TMUV was developed

99 Here we report on a live-attenuated vaccine candidate that contains a 10-nuc

100 that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.

101 In our research, we developed novel live attenuated vaccine candidates against chikungunya v

102 rational development of safe and protective live attenuated vaccine candidates based on genome reorg

103 tical information for the rational design of live attenuated vaccine candidates for other viral hemor

104 thylation as a target for rational design of live attenuated vaccine candidates for RSV and perhaps o

105 This strategy may be useful for generating live attenuated vaccine candidates that prevent disease

106 ified deISGylase activity for development of live attenuated vaccine candidates, and ISG15 as a novel

107 nymous but suboptimal substitutions provides live attenuated vaccine candidates.

108 could form the basis of a new generation of live attenuated vaccine candidates.

109 use of this strain to evaluate the safety of live attenuated vaccine candidates.

110 herefore, ensure the environmental safety of live tick-borne virus vaccine candidates.

111 y stable, highly attenuated, and immunogenic live virus vaccine candidates for RSV.IMPORTANCE Despite

112 bility of a CD-based approach for developing live-attenuated vaccine candidates against human-pathoge

113 tion and provides an approach for generating live-attenuated vaccine candidates for emerging coronavi

114 tor escape mutants and mutations observed in live-attenuated vaccine candidates.

115 Here we demonstrate that live-attenuated Zika virus vaccine candidates containing

116 or the rational design of second-generation, live-attenuated, recombinant JEV vaccine candidates.

117 91, respectively) and for those who received live and inactivated vaccines concurrently compared with

118 ate that pneumococcal conjugate vaccines and live attenuated rotavirus vaccines confer 19.7% (95% con

119 ation and the immune response to single-dose live oral cholera vaccine CVD 103-HgR in Malian adults.

120 to receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) o

121 as developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) th

122 Live RSV vaccine D46/NS2/N/DeltaM2-2-HindIII, attenuated

123 The controversial live attenuated virus vaccine Dengvaxia has boosted the

124 demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the firs

125 e asked if we could improve an NS1-truncated live attenuated influenza vaccine developed for poultry

126 People exposed to serotype 4 infections or a live attenuated serotype 4 vaccine developed neutralizin

127 versus lower respiratory tract and bear upon live attenuated vaccine development.

128 Two girls who had received live attenuated influenza vaccine died, one due to anasa

129 ach to the development of safe and effective live attenuated vaccines directed against VEEV and other

130 ach to the development of safe and effective live attenuated vaccines directed against VEEV and perha

131 ants receiving the monovalent or tetravalent live attenuated DENV vaccine (DLAV), developed by the U.

132 We show that a live-attenuated HSV-1 vaccine elicits humoral immune res

133 id a combination of a commercially available live fowl poxvirus vaccine expressing the H5 influenza v

134 The live attenuated influenza vaccine FluMist has been prove

135 rtance of the production capabilities of the live attenuated influenza vaccine for pandemic preparedn

136 ade an interim recommendation not to use the live attenuated influenza vaccine for the 2016-2017 infl

137 tein is an approach to designing a promising live attenuated vaccine for PEDV.

138 rstanding may also enable the development of live attenuated vaccines for both RSV and other members

139 Live-attenuated pediatric vaccines for intranasal admini

140 A live-attenuated vaccine for RVF, the MP-12 vaccine, is c

141 JUNV), indicating the potential of TCRV as a live-attenuated vaccine for the treatment of Argentine h

142 NV vaccine constructs use the E protein in a live attenuated vaccine format, utilizing a backbone der

143 The live attenuated zoster vaccine generates immune response

144 ses (CoVs), and the inactivation of nsp16 in live attenuated vaccines has been attempted for several

145 Here, we demonstrate that a live-attenuated HSV-1 vaccine has great translational po

146 Live attenuated influenza vaccines have been shown to si

147 Live oral rotavirus (RV) vaccines have shown modest effi

148 Live oral rotavirus vaccines have been developed by seri

149 Although live-attenuated vaccines have been safely administered t

150 ompared with inactivated alone or concurrent live and inactivated vaccines (HR, 0.50; 95% confidence

151 Live attenuated herpes zoster vaccine (HZV) reduces that

152 IAV) that are safe and effective as modified live attenuated (att) virus vaccines (IAV att).

153 Taken together, our data indicate that a live attenuated HSV-2 vaccine impaired for infection of

154 n could improve the safety and efficacy of a live attenuated RSV vaccine.IMPORTANCE RSV binds to the

155 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here w

156 a large body of evidence on the efficacy of live oral rotavirus vaccines in different settings, but

157 assess the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular

158 nitiated a pilot introduction of the Rotarix live, oral rotavirus vaccine in all public health facili

159 hese results raise concerns about the use of live-attenuated HSV-2 vaccines in high HSV-1 prevalence

160 adjuvanted inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG

161 1 envelope (Env) antigens (Ag) for more long-lived, efficacious HIV-1 vaccine-induced B-cell response

162 Live-attenuated influenza vaccine induces both mucosal a

163 V biology, including human host-pathogen and live, attenuated vaccine interactions; host and cell typ

164 A live attenuated RSV vaccine is one of the most promising

165 Live attenuated varicella vaccine is recommended for hea

166 Efficacy of live oral rotavirus vaccines is reduced in low-income co

167 vaccines.IMPORTANCE The genetic stability of live viral vaccines is important for safety and efficacy

168 The live-attenuated Candid#1 vaccine is used in Argentina to

169 tant to prevent the spread of disease, and a live-attenuated MP-12 vaccine is currently the only vacc

170 A live-attenuated MP-12 vaccine is one of the best-charact

171 Rs.IMPORTANCE A chimeric yellow fever-dengue live-attenuated tetravalent vaccine is now being markete

172 rse genetics techniques, we have developed a live-attenuated CIV vaccine (LACIV) for the prevention o

173 e safety and immunogenicity of an avian H5N2 live attenuated influenza vaccine (LAIV H5N2) in healthy

174 Live attenuated influenza vaccine (LAIV) and inactivated

175 al efficacy and safety of a Russian-backbone live attenuated influenza vaccine (LAIV) at two field si

176 omized, placebo-controlled clinical trial of live attenuated influenza vaccine (LAIV) in children age

177 Live attenuated influenza vaccine (LAIV) is an intranasa

178 Whether vaccinating children with intranasal live attenuated influenza vaccine (LAIV) is more effecti

179 ss of the pandemic H1N1 (pH1N1) component in live attenuated influenza vaccine (LAIV) is poor.

180 The live attenuated influenza vaccine (LAIV) is preferential

181 Live attenuated influenza vaccine (LAIV) is recommended

182 The live attenuated influenza vaccine (LAIV) is the preferre

183 Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in it

184 on Practices recommended preferential use of live attenuated influenza vaccine (LAIV) over inactivate

185 The (H1N1)pdm09 live attenuated influenza vaccine (LAIV) strain was chan

186 onses in tonsils and saliva after intranasal live attenuated influenza vaccine (LAIV) vaccination in

187 s of inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) were tested by

188 The live attenuated influenza virus vaccine (LAIV) is prefer

189 We evaluated a Russian-backbone, live, attenuated influenza vaccine (LAIV) for immunogeni

190 dose of either trivalent, Russian-backbone, live, attenuated influenza vaccine (LAIV) or placebo.

191 The effectiveness of the live-attenuated influenza vaccine (LAIV) can vary widely

192 tivated influenza vaccine (TIV) or trivalent live-attenuated influenza vaccine (LAIV) in Thailand.

193 ent 2009 pandemic influenza A(H1N1) virus or live-attenuated influenza vaccine (LAIV) or who had labo

194 l of inactivated influenza vaccine (IIV) and live-attenuated influenza vaccine (LAIV) performed durin

195 Live-attenuated influenza vaccine (LAIV) was licensed fo

196 Here, we report the interactions between live-attenuated influenza vaccine (LAIV), successive pne

197 mbinant, temperature-sensitive H3N8 CIV as a live-attenuated influenza vaccine (LAIV), which was atte

198 Live-attenuated influenza vaccines (LAIV) have been show

199 vated influenza vaccine [TIV] vs. intranasal live, attenuated influenza vaccine [LAIV]) was postulate

200 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) among children

201 ccines (IIV3) and a nasal spray, tetravalent live-attenuated influenza vaccine (LAIV4) were used in p

202 The efficacy of live attenuated influenza vaccines (LAIVs) has been espe

203 However, recent formulations of live attenuated influenza vaccines (LAIVs) have not been

204 Live attenuated influenza vaccines (LAIVs) stimulate a m

205 pproach to generate safer and more efficient live-attenuated influenza virus vaccines (LAIVs) based o

206 completion, and the chances that one or more live attenuated tetravalent vaccines (LATVs) will be int

207 Implementation of live-attenuated vaccines (LAV) will represent a major st

208 Vaccination with live attenuated vaccines (LAVs) is an effective way for

209 Live-attenuated vaccines (LAVs) are the most advanced va

210 RSV live-attenuated vaccines (LAVs) have a history of safe t

211 Implementation of live-attenuated vaccines (LAVs) will represent a major s

212 ve immunity in individuals unable to receive live, attenuated vaccines may have employment implicatio

213 oid and subunit influenza vaccine but not, a live-attenuated viral vaccine, measles vaccine.

214 Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20)

215 gimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by a non-adjuv

216 To secure a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will event

217 forts include high vaccination coverage with live oral polio vaccine (OPV), surveillance for acute fl

218 nzyme cleavage) assay for quality control of live-attenuated oral polio vaccine (OPV).

219 5, the type 2 component was removed from the live-attenuated oral polio vaccine (OPV).

220 The live-attenuated oral poliovirus vaccine (OPV or Sabin va

221 Use of oral live-attenuated polio vaccines (OPV), and injected inact

222 a single intranasal dose of masked trivalent live attenuated influenza vaccine or placebo.

223 d have implications for the development of a live-attenuated KSHV vaccine or vaccine vector.

224 logy of TCRV and also its potential use as a live-attenuated vaccine or a vaccine vector for the trea

225 f TCRV and to explore its potential use as a live-attenuated vaccine or a vaccine vector for the trea

226 Implementation of TCRV as a live-attenuated vaccine or a vaccine vector would be fac

227 Vi-tetanus-toxoid conjugate vaccine (Vi-TT), live oral Ty21a vaccine, or an experimental vaccine (M01

228 ated a candidate A/Anhui/2013(H7N9) pandemic live attenuated influenza vaccine (pLAIV) in healthy adu

229 We have developed pandemic live attenuated influenza vaccines (pLAIVs) against clad

230 A live-attenuated malaria vaccine, Plasmodium falciparum s

231 us, opening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clin

232 As modified mRNA and live-attenuated vaccine platforms can restrict in utero

233 didates in clinical testing are all based on live-virus vaccine platforms and struggle to induce bala

234 s a novel technology to sufficiently deliver live attenuated vaccine powders into the skin.

235 ls spanning the past 28 years, opposition to live-attenuated HSV vaccines predicated on unfounded saf

236 ght substantially improve the performance of live pediatric RSV vaccines presently being developed.

237 ere Shan et al. show that a single dose of a live-attenuated Zika vaccine prevents infection, testis

238 In 2013 England and Wales began to fund a live attenuated influenza vaccine programme for individu

239 ummary, our data indicate that attenuated or live viral vaccines promote cytokine-induced memory-like

240 es.IMPORTANCE Effectiveness of NS1-truncated live attenuated influenza vaccines relies heavily on the

241 The development of live viral vaccines relies on empirically derived phenot

242 Live-attenuated vaccines represent an attractive immuniz

243 CD8(+) T cell responses elicited by a dengue live attenuated virus (DLAV) vaccine resemble those obse

244 role of breast milk secretor status on oral live-attenuated rotavirus vaccine response in breastfed

245 Immunization of mice with live RABV-based vaccines results in accumulation of macr

246 While RABV vaccines are inactivated, the live-attenuated CDV vaccines retain residual virulence f

247 ially be further tested and developed into a live attenuated plague vaccine(s).

248 The use of live attenuated vaccines should be limited to specific s

249 This case illustrates a circumstance when a live viral vaccine should not be used.

250 While live mycobacterial vaccines show promising efficacy, HIV

251 This has implications for the design of live attenuated HPIV3 vaccines; specifically, the antibo

252 The live attenuated vaccine strain Candid #1 (Can) is approv

253 The live, attenuated varicella vaccine strain (vOka) is the

254 d-generation Candid#1 vaccine.IMPORTANCE The live-attenuated Candid#1 vaccine strain of Junin virus i

255 generated a reverse genetics system for the live-attenuated MV vaccine strain Edmonston-Zagreb (EZ),

256 tibility of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replicati

257 A number of live attenuated RSV vaccine strains have been developed

258 , we developed nonreverting, nonreplicating, live attenuated uracil auxotroph vaccine strains in the

259 Live attenuated vaccine strains, such as type I nonrepli

260 ge could be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

261 er, the risk of vaccine-induced disease with live-attenuated vaccines strongly limits their use.

262 Studies with live attenuated Leishmania vaccines such as centrin dele

263 Live attenuated vaccines such as SIV with a deleted nef

264 ldren following immunization with intranasal live attenuated influenza vaccine, suggesting a common r

265 he efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in

266 We are developing a live-attenuated tetravalent dengue vaccine (TDV) candida

267 sults of vaccinating mice with a new type of live attenuated HSV-2 vaccine that is impaired for infec

268 that might be deleted for the development of live attenuated vaccines that would be safer to use in s

269 enetic engineering now enables the design of live viral vaccines that are potentially transmissible.

270 nal Institutes of Health (NIH) has developed live attenuated vaccines to each of the 4 serotypes of d

271 ica serovar Enteritidis DeltaguaBA DeltaclpX live oral vaccines to protect mice against a highly leth

272 Administering a live, attenuated DENV vaccine to healthy subjects signif

273 member of the poxvirus family, was used as a live-virus vaccine to eradicate smallpox worldwide and h

274 etermine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to indu

275 Live-attenuated vaccines typically offer rapid and durab

276 Modified live virus (MLV) vaccines used in the field can persist

277 -mumps-rubella-varicella vaccine (MMRV), one live attenuated varicella vaccine (V) dose given after o

278 use of heterologous flavivirus species as a live attenuated vaccine vector is not likely to generate

279 nstrating the feasibility of using TCRV as a live-attenuated vaccine vector for the treatment of JUNV

280 ammarenaviruses, for their implementation as live-attenuated vaccines or vaccine vectors.IMPORTANCE T

281 ic attenuation and host-range restriction of live attenuated vaccine viruses.

282 The A(H1N1)pdm09 virus strain used in the live attenuated influenza vaccine was changed for the 20

283 Live attenuated influenza vaccine was well tolerated in

284 However, the live attenuated vaccine was found to be ineffective amon

285 fective (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective

286 t the stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV

287 he 2016-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, th

288 The live-attenuated vaccine was used to assess the impact of

289 ruses and human infections, new candidate H5 live attenuated vaccines were developed by using two dif

290 rinary RVF vaccine in the United States is a live-attenuated MP-12 vaccine, which is conditionally li

291 Live attenuated influenza vaccines with truncations in n

292 erpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% agains

293 means to increase the antibody response to a live attenuated HPIV3 vaccine without affecting viral re

294 ing viremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril).

295 cohort of 80 individuals immunized with the live attenuated yellow fever vaccine (YFV-17D) by sampli

296 hy young and older adults immunized with the live attenuated shingles vaccine Zostavax.

297 on against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes with

298 Live attenuated zoster vaccine (Zostavax) was used to te

299 The efficacy and immunogenicity of the live attenuated zoster vaccine (ZVL) have a very-well-de

300 The live attenuated zoster vaccine (ZVL) provides the best e